
Normal healthy adults synthesize cholesterol at a rate of approximately 1g/day
and consume approximately 0.3g/day. A relatively constant level of cholesterol in
the body (150 - 200 mg/dL) is maintained primarily by controlling the level of cholesterol synthesis.
The NIH says that a cardiac risk ratio greater than 7 is considered a warning where
LIPID Typical values (mg/dl) Desirable (mg/dl) Cholesterol (total) 170-210 <200 LDL cholesterol 60-140 <130 HDL cholesterol 35-85 >35 Triglycerides 40-150 <135
HDL - high-density lipoproteins ("good"), 50 % protein, 18 % cholesterol, transports from cells to liver, synthesized in the blood
LDL - low-density lipoproteins ("bad"), 35 % protein, carries, 45 % cholesterol, transports to cells, synthesized in the liver
![]() 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid)
|
Gemfibrozil (a.k.a. Lopid or Lipozid) is a lipid-regulating agent used to lower cholesterol and triglyceride levels. Like Clofibrate and Fenofibrate, it is a derivative of fibric acid and promote rapid VLDL turnover by activating lipoprotein lipase. They also induce the diversion of hepatic free fatty acids from esterification reactions to those of oxidation, thereby decreasing the liver's secretion of triacylglycerol- and cholesterol-rich VLDLs.
Fenofibrate | 2-[4-(4Chlorobenzoyl phenoxy)]-2-methyl propionic acid-1-methyl ethyl ether |
|
The 1985 Nobel Prize in Physiology or Medicine
Michael S. Brown and Joseph L. Goldstein |
|
Other Links: Lipid Digestion and Lipoproteins | 1985 Nobel Prize in Physiology or Medicine: Brown & Goldstein